Loan & DebtJun 25, 2026, 05:27 PM
Vivos Therapeutics Extends Debt-to-Equity Conversion Deadline to Aug 31
AI Summary
Vivos Therapeutics, Inc. has extended its strategic financing agreement with Streeterville Capital, LLC, pushing the deadline for completing a qualifying financing of at least $2.6 million from June 15, 2026, to August 31, 2026. This extension provides Vivos with additional time to raise equity and commence a planned rights offering. Streeterville Capital has reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a combination of preferred and common stock, contingent on Vivos raising the $2.6 million. The move is intended to strengthen Vivos' stockholders' equity and help maintain its Nasdaq listing compliance.
Key Highlights
- Strategic financing agreement with Streeterville Capital extended to August 31, 2026.
- Original deadline for qualifying financing was June 15, 2026.
- Streeterville Capital reaffirmed commitment to convert up to $4.5 million of debt.
- Debt conversion into perpetual preferred stock and common stock.
- Conversion contingent on Vivos raising at least $2.6 million in qualifying financing.
- Extension allows time for planned equity raise and rights offering.
- Aims to strengthen stockholders' equity and maintain Nasdaq listing compliance.
Price Impact
More from VVOS